Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

25 Aug 2022

Abstract excerpt

Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights Tecovirimat's development and patent literature review and is believed to benefit the scientists working on developing MPX treatments. The literature for Tecovirimat was gathered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Plant Virus Research Studies
Share to Poxvirus research and outbreaks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36146675
DOI: 10.3390/v14091870

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox OutbreakPMID 36146675Read ↗

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreakSemantic proximity Read ↗

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read ↗

<i>In silico</i> repurposed drugs against monkeypox virusSemantic proximity Read ↗

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023Semantic proximity Read ↗

Efficacy of Tecovirimat and Cidofovir Against MPXV-Induced Pneumonia, Skin Lesion, and Arthritis in the High-Risk Population-Relevant SCID Mouse ModelSemantic proximity Read ↗

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of CongoSemantic proximity Read ↗

Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.Semantic proximity Read ↗

Monkeypox virus: an ongoing global outbreak hitting the non-endemic countries - a comprehensive review.Semantic proximity Read ↗

Vaccine approach for human monkeypox over the years and current recommendations to prevent the outbreak: a rapid reviewSemantic proximity Read ↗

Vaccine Approach for Human Monkeypox over the Years and Current Recommendations to Prevent the Outbreak: A Rapid ReviewSemantic proximity Read ↗

The Hunt for antipox compounds against Monkeypox Virus Thymidylate Kinase and scaffolding protein leveraging Pharmacophore modeling, molecular docking, ADMET Studies, and molecular dynamics simulation studiesSemantic proximity Read ↗

Monkeypox, a Literature Review: What Is New and Where Does This concerning Virus Come From?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.